Dr. Mikhail Kosiborod with Saint Luke’s Mid-America Heart Institute is leading a clinical trial investing the use of a diabetic drug called dapagliflozin. Apparently, a…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.